Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 01, 2022 10:15 ET | Source: Genmab A/S

Major Shareholder Announcement

Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; July 1, 2022 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets...
June 30, 2022 14:24 ET | Source: Genmab A/S

Genmab to Submit Biologics License Application to U.S. Food and Drug Administration for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)

Company Announcement COPENHAGEN, Denmark; June 30, 2022 – Genmab A/S (Nasdaq: GMAB) today announced its intent to submit a biologics license application (BLA) to the U.S. Food and Drug...
June 27, 2022 04:09 ET | Source: Genmab A/S

Transactions in connection with share buy-back program

Company Announcement COPENHAGEN, Denmark; June 27, 2022 – Genmab A/S (Nasdaq: GMAB). On June 17, 2022 Genmab announced the initiation of a share buy-back program to mitigate dilution from warrant...
June 23, 2022 11:55 ET | Source: Genmab A/S

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Company Announcement COPENHAGEN, Denmark; June 23, 2022 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523,...
June 20, 2022 10:35 ET | Source: Genmab A/S

Major Shareholder Announcement

Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; June 20, 2022 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital...
June 17, 2022 10:38 ET | Source: Genmab A/S

Genmab Announces Initiation of Share Buy-Back Program

Company Announcement Repurchase of up to 370,000 sharesMitigating dilution from warrant exercises and honoring commitments under our Restricted Stock Unit programCompletion expected on August 31,...
June 11, 2022 08:45 ET | Source: Genmab A/S

Genmab Announces Late-Breaking Phase 2 Trial Results of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Relapsed/Refractory Large B-cell Lymphoma (LBCL) Patients Presented at European Hematology Association (EHA) Presidential Symposium

Media Release COPENHAGEN, Denmark; June 11, 2022 Epcoritamab demonstrated clinically meaningful efficacy in challenging to treat, highly refractory LBCL patients, including patients previously...
June 09, 2022 17:17 ET | Source: Genmab A/S

Genmab Commences New Arbitration Under License Agreement With Janssen

Company Announcement COPENHAGEN, Denmark; June 9, 2022 – Genmab A/S (Nasdaq: GMAB) announced today that it has commenced a new arbitration under its license agreement with Janssen Biotech, Inc....
June 09, 2022 14:57 ET | Source: Genmab A/S

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Company Announcement COPENHAGEN, Denmark; June 9, 2022 – Genmab A/S (Nasdaq: GMAB) announced today that the board decided to grant 22,307 restricted stock units and 22,764 warrants to employees of...
June 08, 2022 14:32 ET | Source: Genmab A/S

Genmab to Participate in a Fireside Chat at the Goldman Sachs 43rd Annual Global Healthcare Conference

Media ReleaseCOPENHAGEN, Denmark; June 8, 2022Genmab A/S (Nasdaq: GMAB) announced today that its Chief Financial Officer Anthony Pagano and Chief Development Officer Judith Klimovsky will participate...